S. Laurie

J. Pujol, R. Feld, S. Laurie, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer

A. Wozniak, T. Owonikoko, G. Dy, 2020, Clinical and translational science.

The influence of season and distance to a cancer centre on lung cancer treatment rates

G. Nicholas, P. Wheatley‐Price, Tinghua Zhang, 2017 .

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

A. Oza, D. Jonker, G. Goss, 2016, Journal of Translational Medicine.

A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-Step Desensitization

H. Atkins, J. Bell, M. Roberts, 2006, Clinical Cancer Research.

Chemoradiotherapy for locoregional recurrence of non-small-cell lung cancer after surgical resection: a retrospective analysis.

G. Nicholas, A. Sun, J. Bar, 2013, Clinical lung cancer.

NCIC CTG IND.190 Phase I Trial of Dalotuzumab (MK-0646) in Combination with Cisplatin and Etoposide in Extensive-Stage Small-Cell Lung Cancer

L. Seymour, F. Shepherd, P. Ellis, 2014, Journal of Thoracic Oncology.

A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium

A. Oza, L. Siu, L. Doyle, 2015, British Journal of Cancer.

The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.

S. Laurie, K. Bishay, S. Bourassa-Blanchette, 2020, Current oncology.

A phase I trial to determine the safety, pharmacokinetics, and pharmacodynamics of intercalated BMS-690514 with paclitaxel/carboplatin (PC) in advanced or metastatic solid malignancies

G. Nicholas, A. Gupta, L. Chow, 2013, Cancer Chemotherapy and Pharmacology.

Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?

G. Nicholas, P. Wheatley‐Price, G. Goss, 2018, Current oncology.

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.

H. Feilotter, L. Seymour, F. Shepherd, 2018, Lung cancer.

B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)

E. Duffield, A. Armour, D. Ferry, 2007 .

Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib

G. Pond, J. Dancey, M. Tsao, 2009, Head & neck.

Chemotherapy in the Management of Malignant Tumors of Salivary Gland Origin

A. Argiris, S. Laurie, 2007 .

Malignant Pleural Mesothelioma Outcomes in the Era of Combined Platinum and Folate Antimetabolite Chemotherapy

G. Nicholas, P. Wheatley‐Price, Tinghua Zhang, 2015, Lung cancer international.

The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer

R. Vandermeer, F. Shepherd, E. Spackman, 2022, Therapeutic advances in medical oncology.

CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).

M. Stockler, J. Dancey, M. Tsao, 2020 .

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226)

L. Seymour, P. Ellis, C. Kollmannsberger, 2016 .

Safety of rush immunotherapy to multiple aeroallergens in an adult population.

S. Laurie, D. Khan, S. Harvey, 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study.

L. Seymour, K. Ding, F. Shepherd, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-agent docetaxel (Taxotere) in the treatment of advanced non small-cell lung cancer: clinical concepts and commentary.

M. Kris, S. Laurie, 2000, Clinical lung cancer.

A phase I dose escalation study of a humanized monoclonal antibody to EGFR (hR3) in patients with locally advanced squamous cell cancer of the head and neck (SCCHN) treated with radiotherapy

E. Winquist, V. Venkatesan, A. Nabid, 2002 .

Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012.

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

Chemotherapy in the management of metastatic adenoid cystic carcinoma: A systematic review

D. Pfister, S. Laurie, Y. Su, 2005 .

Prophylactic Cranial Irradiation in Extensive Stage Small Cell Lung Cancer: Outcomes at a Comprehensive Cancer Centre.

W. Kendal, A. Bang, S. Laurie, 2018, International journal of radiation oncology, biology, physics.

P-779 Impact of anemia on outcomes of therapy in limited small celllung cancer (L-SCLC): An analysis of studies performed by the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG)

L. Seymour, K. Ding, R. Feld, 2005 .

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

K. O'Byrne, T. Mok, E. Tan, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.

S. Hotte, M. Roberts, R. Lorence, 2003, Current opinion in molecular therapeutics.

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

K. O'Byrne, Keunchil Park, T. Mok, 2016, The Lancet. Oncology.

Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors

G. Pond, F. Shepherd, P. Ellis, 2005 .

Paraneoplastic manifestations of salivary gland tumours: A case report and review.

S. Laurie, B. Purgina, A. Nasser, 2020, Oral oncology.

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC)

S. Gettinger, F. Shepherd, D. Gerber, 2014 .

Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.

D. Hayes, G. Pond, J. Dancey, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and / or erbB 2 Expressing Adenoid Cystic Carcinoma and Non – Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands

D. Hayes, G. Pond, J. Dancey, 2007 .

ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Jeffrey W. Scott, Keunchil Park, Dong-Wan Kim, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Bingshu E. Chen, A. Tinker, H. Feilotter, 2022, Nature Communications.

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

S. Gettinger, F. Shepherd, D. Gerber, 2017, The Lancet. Oncology.

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic therapy in the palliative management of advanced salivary gland cancers.

L. Licitra, S. Laurie, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer.

K. Ang, G. Weinstein, D. Pfister, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.

A. Ho, D. Pfister, E. Sherman, 2011, The Lancet. Oncology.

Unmet needs for patients with salivary gland cancer.

A. Ho, D. Pfister, S. Laurie, 2016, Oral oncology.

A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer

D. Tu, W. Parulekar, L. Siu, 2010, Cancer.

Primary cutaneous adenoid cystic carcinoma with brain metastases: case report and literature review

R. Glikstein, P. Hanagandi, J. Michaud, 2016, Journal of cutaneous pathology.

Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients

M. Tsao, F. Shepherd, P. Ellis, 2016, British Journal of Cancer.

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

G. Weinstein, Nofisat Ismaila, Q. Le, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.

M. Stockler, L. Seymour, K. Ding, 2014, European journal of cancer.

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview.

G. Nicholas, S. Laurie, N. Daaboul, 2018, Current oncology.

Systemic Therapy in Nonsmall Cell Lung Cancer and the Role of Biomarkers in Selection of Treatment.

S. Laurie, B. Lo, 2021, Thoracic surgery clinics.

A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.

L. Seymour, M. Tsao, D. Tu, 2020, Lung cancer.

Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.

M. Tsao, A. Hansen, S. Bratman, 2017, Cancer treatment reviews.

OA16.02 The Economic Value of Liquid Biopsy for Genomic Profiling in Advanced Non-Small Cell Lung Cancer

R. Vandermeer, F. Shepherd, N. Leighl, 2021, Journal of Thoracic Oncology.

Demonstrating the value of liquid biopsy for lung cancer in a public health care system.

R. Vandermeer, F. Shepherd, N. Leighl, 2020 .

Malignant mesothelioma: Canadian perspective and research directions

P. Baas, R. Feld, N. Murray, 2008, Current Oncology.

Phase I-IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours.

N. Hanna, J. Baselga, R. Herbst, 2013, European journal of cancer.

Role of epidermal growth factor receptor inhibitors in epidermal growth factor receptor wild-type non-small-cell lung cancer.

G. Goss, S. Laurie, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514.

R. Herbst, F. Shepherd, E. Felip, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer

G. Nicholas, S. Laurie, Sandra Froeschl, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis

S. Laurie, S. Parlow, K. Bishay, 2018, Journal of immunotherapy.

Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.

L. Seymour, F. Shepherd, P. Ellis, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC

S. Gettinger, F. Shepherd, D. Gerber, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185

H. Mackay, E. Eisenhauer, L. Seymour, 2007, Current oncology.

Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not.

G. Nicholas, P. Wheatley‐Price, Tinghua Zhang, 2016, Lung cancer.

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck.

Kelvin K. W. Chan, L. Siu, Siddharth Singh, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of dacomitinib , an oral pan-human EGF receptor ( HER ) inhibitor , as fi rst-line treatment in recurrent and / or metastatic squamous-cell carcinoma of the head and neck †

A. Razak, L. Siu, S. Chia, 2013 .

The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group.

L. Seymour, K. Ding, F. Shepherd, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Ocular metastasis of lung adenocarcinoma with ELM4-ALK translocation: A case report with a review of the literature.

H. Sekhon, S. Gilberg, S. Laurie, 2013, Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society.

Inpatients versus outpatients with advanced non-small cell lung cancer: Characteristics and outcomes.

G. Nicholas, P. Wheatley‐Price, Tinghua Zhang, 2019, Cancer treatment and research communications.

Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.

S. Banerji, M. Tsao, G. Nicholas, 2019, Current oncology.

Reply to F. Gelsomino et al.

G. Goss, S. Laurie, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial

K. O'Byrne, T. Mok, E. Tan, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

A. Oza, D. Jonker, G. Goss, 2016, Journal of Translational Medicine.

Targeted therapy in BRAF-mutated lung adenocarcinoma.

S. Laurie, 2016, The Lancet. Oncology.

ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.

Bingshu E. Chen, L. Seymour, M. Tsao, 2016, Cancer epidemiology.

CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer.

M. Stockler, J. Dancey, M. Tsao, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.

L. Prentice, L. Seymour, G. Nicholas, 2019, Lung cancer.

Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens

L. Seymour, G. Nicholas, D. Tu, 2018, Investigational New Drugs.

Phase I and pharmacological study of two schedules of the antifolate edatrexate in combination with cisplatin.

M. Kris, D. Pfister, K. Pisters, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group.

L. Seymour, F. Shepherd, D. Tu, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.

G. Pond, M. Levine, C. Addison, 2017, Lung cancer.

Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials Group

L. Seymour, G. Nicholas, T. Reiman, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC)

G. Pond, A. Bezjak, F. Shepherd, 2008 .

Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer.

A. Bezjak, F. Shepherd, A. Hope, 2016, Clinical lung cancer.

Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status.

F. Hirsch, E. Duffield, A. Armour, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.

A. Oza, M. Tsao, F. Shepherd, 2014, Clinical lung cancer.

Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.

L. Seymour, K. Ding, F. Shepherd, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

1548P A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma

M. Gounder, N. Yamamoto, T. Bauer, 2021, Annals of Oncology.

Prognostic factors in the radical nonsurgical treatment of stage IIIB non-small-cell lung cancer.

J. Pantarotto, E. Sabri, P. Wheatley‐Price, 2014, Clinical lung cancer.

BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

Bingshu E. Chen, D. Cescon, L. Seymour, 2016, Clinical Cancer Research.

P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC: Topic: Miscellaneous

Keunchil Park, R. Dziadziuszko, Dong-Wan Kim, 2017 .

Association between Anemia Arising during Therapy and Outcomes of Chemoradiation for Limited Small-cell Lung Cancer

G. Nicholas, S. Dahrouge, S. Laurie, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Anaphylaxis to isosulfan blue.

R. Gruchalla, S. Laurie, D. Khan, 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies—results of a phase I dose-escalation study

D. Camidge, L. Chow, D. Jonker, 2013, Investigational New Drugs.

Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma

R. Doebele, D. Camidge, L. Chow, 2013, Cancer Chemotherapy and Pharmacology.

A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer

L. Tye, D. Camidge, L. Chow, 2011, Cancer Chemotherapy and Pharmacology.

A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.

K. Gelmon, M. Sawyer, P. Ellis, 2019, Journal of Clinical Oncology.

IND.175: Phase I study of daily oral AZD2171, a vascular endothelial growth factor receptor inhibitor (VEGFRI), in combination with gemcitabine and cisplatin (G/C) in patients with advanced non-small cell lung cancer (ANSCLC): A study of the NCIC Clinical Trials Group

L. Seymour, F. Shepherd, N. Leighl, 2007 .

Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

S. Banerji, M. Tsao, S. Kamel‐Reid, 2016, Current oncology.

Towards evidence-based response criteria for cancer immunotherapy

L. Seymour, E. de Vries, E. Garralda, 2023, Nature communications.

The Principles of Weight of Evidence Validation of Test Methods and Testing Strategies

Zuang Valerie, Casati Silvia, Coecke Sandra, 2006 .

Phase II Testing of Sunitinib: The NCIC CTG IND Program Trials IND.182 - 185

H. Mackay, E. Eisenhauer, L. Seymour, 2007 .

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

P. Postmus, Keunchil Park, R. Dziadziuszko, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PS02.20 Subsequent Therapies Post-Afatinib Among Patients with EGFR Mutation-Positive (EGFRm+) NSCLC in LUX-Lung 3, 6 and 7: Topic: Medical Oncology

L. Sequist, Wenbo Tang, L. Paz-Ares, 2017 .

OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update

S. Gettinger, F. Shepherd, D. Gerber, 2017 .

A phase II trial of gefitinib in patients with malignant pleural mesothelioma (MPM)

H. Anderson, Christopher W. Lee, S. Laurie, 2008 .

Pilot trial of ZD1839 (IressaTM), an oral inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, in combination with carboplatin (C) and paclitaxel (P) in previously untreated advanced non-small cell lung cancer (NSCLC)

M. Kris, V. Miller, Douglas B. Johnson, 2000 .

ORAL01.03: CheckMate 012: Safety and Efficacy of First‐Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology

S. Gettinger, F. Shepherd, D. Gerber, 2016, Journal of Thoracic Oncology.

Abstract CT212: A ctDNA-directed, multi-center phase II study of molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer: Analysis of Stage 1 of CCTG BR.36

J. Dancey, K. Ding, G. Nicholas, 2023, Cancer Research.

OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC

P. Postmus, Keunchil Park, R. Dziadziuszko, 2017 .

The Impact of Baseline Edmonton Symptom Assessment Scale Scores on Treatment and Survival in Patients With Advanced Non–small‐cell Lung Cancer

G. Nicholas, Tinghua Zhang, G. Goss, 2018, Clinical lung cancer.

Successful clarithromycin desensitization in a multiple macrolide-allergic patient.

S. Laurie, D. Khan, E. Ruiz-Huidobro, 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

G. Pond, Y. Yen, F. Shepherd, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

L. Siu, Siddharth Singh, S. Chia, 2010 .

Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic

Mohammed I. Alghamdi, Kevin C. Chu, E. R. Lloyd, 2021, The British journal of surgery.

Phase I multicenter trial of BMS-690514: Safety, pharmacokinetic profile, biological effects, and early clinical evaluation in patients with advanced solid tumors and non-small cell lung cancer

N. Hanna, R. Herbst, F. Shepherd, 2008 .

Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)

K. O'Byrne, Keunchil Park, T. Mok, 2016 .

American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer.

G. Weinstein, W. Mendenhall, L. Harrison, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.

R. Heist, W. Edenfield, C. Li, 2016 .

IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.

L. Seymour, M. Mencoboni, F. Grosso, 2023, Journal of Clinical Oncology.

The MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study

M. Teufel, M. Gounder, T. Bauer, 2023, Cancer discovery.

Brief Report: Canadian Cancer Trials Group IND.227: A Phase II randomized study of pembrolizumab in patients with advanced malignant pleural mesothelioma (NCT02784171).

C. Gridelli, L. Cavanna, L. Seymour, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Ocular metastasis of lung adenocarcinoma with ELM4-ALK translocation: A case report with a review of the literature.

H. Sekhon, S. Gilberg, S. Laurie, 2013, Saudi Journal of Ophthalmology.

BRM Promoter Polymorphisms and Survival of Advanced Non–Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial

Bingshu E. Chen, D. Cescon, L. Seymour, 2016, Clinical Cancer Research.

Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients?

G. Nicholas, Tinghua Zhang, G. Goss, 2018, Current oncology.

P84.05 Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK+ NSCLC: Final Report of the ASCEND-8 Trial

A. Ardizzoni, B. Cho, M. Izquierdo, 2021 .

Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial.

Kelvin K. W. Chan, S. Kamel‐Reid, L. Siu, 2013 .

Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

L. Siu, S. Chia, S. Hotte, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The clinical course of nonsmall cell lung carcinoma in survivors of Hodgkin disease

K. Rosenzweig, M. Kris, V. Rusch, 2002, Cancer.